» Articles » PMID: 22149928

Aerosolized Clindamycin is Superior to Aerosolized Dexamethasone or Clindamycin-dexamethasone Combination in the Treatment of Severe Porphyromonas Gingivalis Aspiration Pneumonia in an Experimental Murine Model

Overview
Journal Exp Lung Res
Publisher Informa Healthcare
Specialty Pulmonary Medicine
Date 2011 Dec 14
PMID 22149928
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Adjunctive corticosteroid treatment to reduce excessive local inflammatory response in pneumonia is controversial. To study the effects of an early local adjunct dexamethasone treatment on the course of pneumonia and inflammatory/cytokine response, mice were intratracheally inoculated with live Porphyromonas gingivalis and treated with either clindamycin (C), dexamethasone (D), C+D combination, or were not treated (Pg). Six mice from each group were euthanized at 6, 24, 72, and 168 hours after inoculation. Levels of tumor necrosis factor (TNF)-α, soluble TNF-α receptors (sTNFR1 and sTNFR2), interleukin (IL)-1β, and IL-6 in the serum and lung-homogenate supernatant were determined. Lung samples were histopathologically assessed and all findings compared to those found in 24 sham-inoculated mice (phosphate-buffered saline [PBS]). Severe P. gingivalis-induced bronchopneumonia progressed from 24 hours, peaked at 72 hours, and resolved after 168 hours with changes in local and systemic cytokine levels. Clindamycin-treated mice developed only mild bronchopneumonia that resolved fast (72 hours) with an early (6-24 hours) normalization of local and systemic cytokine levels. Similar course of pneumonia and cytokine level changes were observed in mice treated with C+D, but later. Early (6-24 hours) local elevation of sTNFRs was observed in C and C+D groups of mice, whereas nontreated (Pg) mice had increased systemic sTNFRs. Severe bronchopneumonia with delayed resolution was observed in D-group mice, with an early local and systemic decrease in sTNFR1 and persistent elevation of local TNF-α. Clindamycin or a clindamycin-dexamethasone combination treatment significantly improves the course of P. gingivalis-aspiration pneumonia, but more so if clindamycin alone is used. A favorable course of pneumonia seems to be associated with an early elevation of sTNFRs and normalization of TNF-α.

Citing Articles

Advances in the relationship between periodontopathogens and respiratory diseases (Review).

Zhang Z, Wen S, Liu J, Ouyang Y, Su Z, Chen D Mol Med Rep. 2024; 29(3).

PMID: 38240101 PMC: 10828996. DOI: 10.3892/mmr.2024.13166.


Components/Secretions Synergistically Enhance Pneumonia Caused by in Mice.

Okabe T, Kamiya Y, Kikuchi T, Goto H, Umemura M, Suzuki Y Int J Mol Sci. 2021; 22(23).

PMID: 34884507 PMC: 8657795. DOI: 10.3390/ijms222312704.


Clindamycin as an Alternative Option in Optimizing Periodontal Therapy.

Luchian I, Goriuc A, Martu M, Covasa M Antibiotics (Basel). 2021; 10(7).

PMID: 34356735 PMC: 8300806. DOI: 10.3390/antibiotics10070814.


Gingipains: Critical Factors in the Development of Aspiration Pneumonia Caused by Porphyromonas gingivalis.

Benedyk M, Mydel P, Delaleu N, Plaza K, Gawron K, Milewska A J Innate Immun. 2015; 8(2):185-98.

PMID: 26613585 PMC: 4801669. DOI: 10.1159/000441724.


Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.

Velkov T, Abdul Rahim N, Zhou Q, Chan H, Li J Adv Drug Deliv Rev. 2014; 85:65-82.

PMID: 25446140 PMC: 4429008. DOI: 10.1016/j.addr.2014.11.004.